메뉴 건너뛰기




Volumn 2, Issue 6, 2003, Pages 473-488

Therapeutic strategies for rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CIPEMASTAT; CYCLOSPORIN A; ETANERCEPT; FLAVONOID; GLIOTOXIN; GLUCOCORTICOID; GOLD SALT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID; PARTHENOLIDE; PENICILLAMINE; PROTEASOME INHIBITOR; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TANOMASTAT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR DERIVATIVE; UNINDEXED DRUG;

EID: 0038131975     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1109     Document Type: Review
Times cited : (731)

References (256)
  • 1
    • 0035012803 scopus 로고    scopus 로고
    • The epidemiology of rheumatoid arthritis
    • Gabriel, S. E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27, 269-282 (2001).
    • (2001) Rheum. Dis. Clin. North Am. , vol.27 , pp. 269-282
    • Gabriel, S.E.1
  • 2
    • 0031732074 scopus 로고    scopus 로고
    • The longterm outcome of rheumatoid arthritis. Work disability: A prospective 18 year study of 816 patients
    • Wolfe, F. E. & Hawley, D. J. The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients. J. Rheumatol. 25, 2108-2117 (1998).
    • (1998) J. Rheumatol. , vol.25 , pp. 2108-2117
    • Wolfe, F.E.1    Hawley, D.J.2
  • 3
    • 0028105830 scopus 로고
    • Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures
    • Pincus, T. E., Brooks, R. H. & Callahan, L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures Ann. Intern. Med. 120, 26-34 (1994).
    • (1994) Ann. Intern. Med. , vol.120 , pp. 26-34
    • Pincus, T.E.1    Brooks, R.H.2    Callahan, L.F.3
  • 4
    • 0033001678 scopus 로고    scopus 로고
    • An assessment of the annual and long-term direct costs: The impact of poor function and functional decline
    • Yelin, E. & Wanke, L. A. An assessment of the annual and long-term direct costs: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209-1218 (1999).
    • (1999) Arthritis Rheum. , vol.42 , pp. 1209-1218
    • Yelin, E.1    Wanke, L.A.2
  • 5
    • 0034062017 scopus 로고    scopus 로고
    • The costs of rheumatoid arthritis: An international long-term view
    • Pugner, K. M., Scott, D. I., Holmes, J. W. & Hieke, K. The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305-320 (2000).
    • (2000) Semin. Arthritis Rheum. , vol.29 , pp. 305-320
    • Pugner, K.M.1    Scott, D.I.2    Holmes, J.W.3    Hieke, K.4
  • 6
    • 0028813226 scopus 로고
    • Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity
    • Smolen, J. S. et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 38, 38-43 (1995).
    • (1995) Arthritis Rheum. , vol.38 , pp. 38-43
    • Smolen, J.S.1
  • 7
    • 84861808622 scopus 로고    scopus 로고
    • Epidemiology and genetics of rheumatoid arthritis
    • Silman, A. J. & Pearson, J. E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4 (Suppl 3), S268-S272 (2002).
    • (2002) Arthritis Res. , vol.4 , Issue.SUPPL. 3
    • Silman, A.J.1    Pearson, J.E.2
  • 8
    • 0012964271 scopus 로고    scopus 로고
    • HLA molecules, bacteria and autoimmunity
    • Ebringer, A. & Wilson, C. HLA molecules, bacteria and autoimmunity. J. Med. Microbial. 49, 305-311 (2000).
    • (2000) J. Med. Microbial. , vol.49 , pp. 305-311
    • Ebringer, A.1    Wilson, C.2
  • 9
    • 0034984010 scopus 로고    scopus 로고
    • From reactive arthritis to rheumatoid arthritis
    • Toivanen, P. From reactive arthritis to rheumatoid arthritis. J. Autoimmun 16, 369-371 (2001).
    • (2001) J. Autoimmun. , vol.16 , pp. 369-371
    • Toivanen, P.1
  • 10
    • 0024604643 scopus 로고
    • Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
    • van der Heijde D. M. et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1, 1036-1038 (1989).
    • (1989) Lancet , vol.1 , pp. 1036-1038
    • van der Heijde, D.M.1
  • 11
    • 0014816759 scopus 로고
    • The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine
    • Jaffe, I. A. The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine. Arthritis Rheum. 13, 436-443 (1970).
    • (1970) Arthritis Rheum. , vol.13 , pp. 436-443
    • Jaffe, I.A.1
  • 12
    • 0028280174 scopus 로고
    • Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial
    • Kloppenburg, M. A. et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 37, 629-636 (1994).
    • (1994) Arthritis Rheum. , vol.37 , pp. 629-636
    • Kloppenburg, M.A.1
  • 13
    • 0036056315 scopus 로고    scopus 로고
    • Toll-like receptors: A family of pattern-recognition receptors in mammals
    • REVIEWS3011
    • Armant, M. A. & Fenton, M. J. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. 3, REVIEWS3011 (2002).
    • (2002) Genome Biol. , vol.3
    • Armant, M.A.1    Fenton, M.J.2
  • 14
    • 0036067659 scopus 로고    scopus 로고
    • Toll receptors, CD14, and macrophage activation and deactivation by LPS
    • Dobrovolskaia M. A. & Vogel, S. N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes. Infect. 4, 903-914 (2002).
    • (2002) Microbes. Infect. , vol.4 , pp. 903-914
    • Dobrovolskaia, M.A.1    Vogel, S.N.2
  • 16
    • 0034756143 scopus 로고    scopus 로고
    • Rheumatoid arthritis is more than cytokines: Autoimmunity and rheumatoid arthritis
    • Smolen, J. S. & Steiner, G. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum. 44, 2218-2220 (2001).
    • (2001) Arthritis Rheum. , vol.44 , pp. 2218-2220
    • Smolen, J.S.1    Steiner, G.2
  • 17
    • 0012663097 scopus 로고    scopus 로고
    • Autoantibodies in rheumatoid arthritis and their clinical significance
    • Steiner, G. & Smolen, J. S. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4, S1-S5 (2002).
    • (2002) Arthritis Res. , vol.4
    • Steiner, G.1    Smolen, J.S.2
  • 18
    • 20244368182 scopus 로고    scopus 로고
    • Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
    • Fritsch, R. et al. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J. Immunol. 169, 1068-1076 (2002).
    • (2002) J. Immunol. , vol.169 , pp. 1068-1076
    • Fritsch, R.1
  • 19
    • 0031974911 scopus 로고    scopus 로고
    • Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies
    • Schellekens, G. A., de Jong, B. A. W., van den Hoogen, F. H. J., van de Putte, L. B. A. & van Venrooj, W. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101, 273-281 (1998).
    • (1998) J. Clin. Invest. , vol.101 , pp. 273-281
    • Schellekens, G.A.1    de Jong, B.A.W.2    van den Hoogen, F.H.J.3    van de Putte, L.B.A.4    van Venrooj, W.5
  • 20
    • 0036188754 scopus 로고    scopus 로고
    • Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom
    • MacKay, K. et al. Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum. 413, 632-639 (2002).
    • (2002) Arthritis Rheum. , vol.413 , pp. 632-639
    • MacKay, K.1
  • 21
    • 0032703306 scopus 로고    scopus 로고
    • Cytokine production by synovial T cells in rheumatoid arthritis
    • Steiner, G. et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38, 202-213 (1999).
    • (1999) Rheumatology (Oxford) , vol.38 , pp. 202-213
    • Steiner, G.1
  • 22
    • 0030021790 scopus 로고    scopus 로고
    • The role of T-lymphocytes and cytokines in rheumatoid arthritis
    • Smolen, J. S. et al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand. J. Rheumatol. 25, 1-4 (1996).
    • (1996) Scand. J. Rheumatol. , vol.25 , pp. 1-4
    • Smolen, J.S.1
  • 24
    • 0030459439 scopus 로고    scopus 로고
    • Shift toward T lymphocytes T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
    • Dolhain, R. J. et al. Shift toward T lymphocytes T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 39, 1961-1969 (1996).
    • (1996) Arthritis Rheum. , vol.39 , pp. 1961-1969
    • Dolhain, R.J.1
  • 25
    • 0030459439 scopus 로고    scopus 로고
    • Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
    • Dolhain, R. J. et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 39, 1961-1969 (1996).
    • (1996) Arthritis Rheum. , vol.39 , pp. 1961-1969
    • Dolhain, R.J.1
  • 26
    • 0033168136 scopus 로고    scopus 로고
    • Altered memory T cell differentiation in patients with early rheumatoid arthritis
    • Skapenko, A. et al. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J. Immunol. 163, 491-499 (1999).
    • (1999) J. Immunol. , vol.163 , pp. 491-499
    • Skapenko, A.1
  • 28
    • 0027465503 scopus 로고
    • Cell surface glycoproteins expressed on activated human T cells induce production of interleukin 1 beta by monocytes: A possible role of CD69
    • Isler, P., Vey, E., Zhang, J. H. & Dayer, J. M. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin 1 beta by monocytes: a possible role of CD69. Eur. Cytokine Netw. 4, 15-23 (1993),
    • (1993) Eur. Cytokine Netw. , vol.4 , pp. 15-23
    • Isler, P.1    Vey, E.2    Zhang, J.H.3    Dayer, J.M.4
  • 29
    • 0031042456 scopus 로고    scopus 로고
    • Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
    • McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
    • (1997) Nature Med. , vol.3 , pp. 189-195
    • McInnes, I.B.1    Leung, B.P.2    Sturrock, R.D.3    Field, M.4    Liew, F.Y.5
  • 30
    • 0027240829 scopus 로고
    • Macrophage activation by T cells: Cognate and non-cognate signals
    • Stout, R. D. Macrophage activation by T cells: cognate and non-cognate signals. Curr. Opin. Immunol. 5, 398-403 (1993).
    • (1993) Curr. Opin. Immunol. , vol.5 , pp. 398-403
    • Stout, R.D.1
  • 31
    • 0032055597 scopus 로고    scopus 로고
    • IL-17 stimulates the production of proinflammatory cytokines, IL-1 beta and TNF-alpha, by human macrophages
    • Jovanovic, D. V. et al. IL-17 stimulates the production of proinflammatory cytokines, IL-1 beta and TNF-alpha, by human macrophages. J. Immunol. 160, 3513-3521 (1998).
    • (1998) J. Immunol. , vol.160 , pp. 3513-3521
    • Jovanovic, D.V.1
  • 33
    • 0027486150 scopus 로고
    • Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines
    • Bombara, M. P. et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J. Leukoc. Biol. 54, 399-406 (1993).
    • (1993) J. Leukoc. Biol. , vol.54 , pp. 399-406
    • Bombara, M.P.1
  • 34
    • 0017325645 scopus 로고
    • Collagenase production by rheumatoid synovial cells: Stimulation by a human lymphocyte factor
    • Dayer, J. M., Graham, R., Russel, G. & Krane, S. M. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 181-183 (1977).
    • (1977) Science , vol.195 , pp. 181-183
    • Dayer, J.M.1    Graham, R.2    Russel, G.3    Krane, S.M.4
  • 35
    • 0023694150 scopus 로고
    • Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis
    • Eastgate, J. A. et al. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2, 706-709 (1988).
    • (1988) Lancet , vol.2 , pp. 706-709
    • Eastgate, J.A.1
  • 36
    • 0025255530 scopus 로고
    • Quantitative analysis of cytokine gene expression in rheumatoid arthritis
    • Firestein, G. S., Alvaro-Gracia, J. M. & Maki, R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144, 3347-3353 (1990).
    • (1990) J. Immunol. , vol.144 , pp. 3347-3353
    • Firestein, G.S.1    Alvaro-Gracia, J.M.2    Maki, R.3
  • 37
    • 0022606130 scopus 로고
    • Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid
    • Miossec, P., Dinarello, C. A. & Ziff, M. Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum. 29, 461-470 (1986).
    • (1986) Arthritis Rheum. , vol.29 , pp. 461-470
    • Miossec, P.1    Dinarello, C.A.2    Ziff, M.3
  • 38
    • 0030903094 scopus 로고    scopus 로고
    • The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis
    • Okamoto, H. et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum.40, 1096-1105 (1997).
    • (1997) Arthritis Rheum. , vol.40 , pp. 1096-1105
    • Okamoto, H.1
  • 39
    • 0023712236 scopus 로고
    • Detection of tumor-necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum
    • Saxne, T., Palladino, M. A. Jr, Heinegard, D., Talal, N. & Woliheim, F. A. Detection of tumor-necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31, 1041-1045 (1988).
    • (1988) Arthritis Rheum. , vol.31 , pp. 1041-1045
    • Saxne, T.1    Palladino Jr., M.A.2    Heinegard, D.3    Talal, N.4    Woliheim, F.A.5
  • 40
    • 0026091413 scopus 로고
    • Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
    • Chu, C. Q., Field, M., Feldmann, M. & Maini, R. N. Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125-1132 (1991).
    • (1991) Arthritis Rheum. , vol.34 , pp. 1125-1132
    • Chu, C.Q.1    Field, M.2    Feldmann, M.3    Maini, R.N.4
  • 41
    • 0024314554 scopus 로고
    • Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
    • Brennan, F. M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).
    • (1989) Lancet , vol.2 , pp. 244-247
    • Brennan, F.M.1    Chantry, D.2    Jackson, A.3    Maini, R.4    Feldmann, M.5
  • 42
    • 0022472749 scopus 로고
    • Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1
    • Dinarello C. A. et al. Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1. J. Exp. Med. 163, 1433-1450 (1986).
    • (1986) J. Exp. Med. , vol.163 , pp. 1433-1450
    • Dinarello, C.A.1
  • 43
    • 0036839148 scopus 로고    scopus 로고
    • Role of interleukin 15 and interleukin 18 in inflammatory response
    • Liew, F. Y. & McInnes, I. B. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann. Rheum. Dis. 61 S2, ii100-ii102 (2002).
    • (2002) Ann. Rheum. Dis. , vol.61 , Issue.S2
    • Liew, F.Y.1    McInnes, I.B.2
  • 44
    • 0242388249 scopus 로고    scopus 로고
    • Smolen J. S. & Lipsky, P. L. (eds) (Dunitz, London)
    • Folkman J. in Targeted Therapies in Rheumatology Smolen J. S. & Lipsky, P. L. (eds) 111-131 (Dunitz, London, 2003).
    • (2003) Targeted Therapies in Rheumatology , pp. 111-131
    • Folkman, J.1
  • 45
    • 0036009115 scopus 로고    scopus 로고
    • NF-κB at the crossroads of life and death
    • Karin, M. & Lin, A. NF-κB at the crossroads of life and death. Nature Immunol. 3, 221-227 (2002).
    • (2002) Nature Immunol. , vol.3 , pp. 221-227
    • Karin, M.1    Lin, A.2
  • 46
    • 0036098552 scopus 로고    scopus 로고
    • AP-1 as a regulator of cell life and death
    • Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nature Cell Biol. 4, 131-136 (2002).
    • (2002) Nature Cell Biol. , vol.4 , pp. 131-136
    • Shaulian, E.1    Karin, M.2
  • 48
    • 0037280317 scopus 로고    scopus 로고
    • Novel mechanistic concepts for the control of leukocyte transmigration: Specialization of integrins, chemokines, and junctional molecules
    • Weber, C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J. Mol. Med. 81, 4-19 (2003).
    • (2003) J. Mol. Med. , vol.81 , pp. 4-19
    • Weber, C.1
  • 49
    • 0028227917 scopus 로고
    • Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis
    • Zvaifler, N. J. & Firestein, G. S. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum. 37, 783-789 (1994).
    • (1994) Arthritis Rheum. , vol.37 , pp. 783-789
    • Zvaifler, N.J.1    Firestein, G.S.2
  • 50
    • 0031894140 scopus 로고    scopus 로고
    • Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
    • Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998).
    • (1998) Am. J. Pathol. , vol.152 , pp. 943-951
    • Gravallese, E.M.1
  • 51
    • 0034284970 scopus 로고    scopus 로고
    • Bone resorption by osteoclasts
    • Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
    • (2000) Science , vol.289 , pp. 1504-1508
    • Teitelbaum, S.L.1
  • 52
    • 0036853902 scopus 로고    scopus 로고
    • Osteoclasts are essential for TNF-α-mediated joint destruction
    • Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
    • (2002) J. Clin. Invest. , vol.110 , pp. 1419-1427
    • Redlich, K.1
  • 53
    • 0036226744 scopus 로고    scopus 로고
    • Local production of complement proteins in rheumatoid arthritis synovium
    • Neumann, E. et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46, 934-945 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 934-945
    • Neumann, E.1
  • 54
    • 0016817748 scopus 로고
    • Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage
    • Ishikawa, H., Smiley, J. D. & Ziff, M, Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. Arthritis Rheum. 18, 563-576 (1975).
    • (1975) Arthritis Rheum. , vol.18 , pp. 563-576
    • Ishikawa, H.1    Smiley, J.D.2    Ziff, M.3
  • 55
    • 0034192427 scopus 로고    scopus 로고
    • Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors
    • Kleinau S., Martinsson, P. & Heyman, B. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J. Exp. Med. 191, 1611-1616 (2000).
    • (2000) J. Exp. Med. , vol.191 , pp. 1611-1616
    • Kleinau, S.1    Martinsson, P.2    Heyman, B.3
  • 56
    • 0036307544 scopus 로고    scopus 로고
    • Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity
    • Elenkov, I. J. & Chrousos, G. P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N. Y. Acad Sci. 966, 290-303 (2002).
    • (2002) Ann. N. Y. Acad Sci. , vol.966 , pp. 290-303
    • Elenkov, I.J.1    Chrousos, G.P.2
  • 57
    • 0034811016 scopus 로고    scopus 로고
    • Control of autoimmunity by regulatory T cells
    • Shevach, E. M. et al. Control of autoimmunity by regulatory T cells. Adv. Exp. Med. Biol. 490, 21-32 (2001).
    • (2001) Adv. Exp. Med. Biol. , vol.490 , pp. 21-32
    • Shevach, E.M.1
  • 58
    • 0030066368 scopus 로고    scopus 로고
    • Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
    • ten Wolde, S. et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347, 347-352 (1996).
    • (1996) Lancet , vol.347 , pp. 347-352
    • ten Wolde, S.1
  • 59
    • 0030963885 scopus 로고    scopus 로고
    • Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation
    • ten Wolde, S., Hermans, J., Breedveld, F. C. & Dijkmans, B. A. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann. Rheum. Dis. 56, 235-239 (1997).
    • (1997) Ann. Rheum. Dis. , vol.56 , pp. 235-239
    • ten Wolde, S.1    Hermans, J.2    Breedveld, F.C.3    Dijkmans, B.A.4
  • 60
    • 84960582159 scopus 로고
    • Efficacy of methotrexate in rheumatoid arthritis
    • Weinblatt, M. E. Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol. 34, S43-S48 (1995).
    • (1995) Br. J. Rheumatol. , vol.34
    • Weinblatt, M.E.1
  • 61
    • 0034735827 scopus 로고    scopus 로고
    • A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    • Bathon, J. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
    • (2000) N. Engl. J. Med. , vol.343 , pp. 1586-1593
    • Bathon, J.M.1
  • 62
    • 0033053835 scopus 로고    scopus 로고
    • Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
    • Smolen, J. S. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353, 259-266 (1999).
    • (1999) Lancet , vol.353 , pp. 259-266
    • Smolen, J.S.1
  • 63
    • 0033557695 scopus 로고    scopus 로고
    • Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression
    • Manna, S. K. & Aggarwal, B. B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol. 162, 2095-2102 (1999).
    • (1999) J. Immunol. , vol.162 , pp. 2095-2102
    • Manna, S.K.1    Aggarwal, B.B.2
  • 64
    • 0032519992 scopus 로고    scopus 로고
    • Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production
    • Siemasko, K. F. et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160, 1581-1588 (1998).
    • (1998) J. Immunol. , vol.160 , pp. 1581-1588
    • Siemasko, K.F.1
  • 65
    • 0025080342 scopus 로고
    • Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
    • Wolfe, F., Hawley, D. J. & Cathey, M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J. Rheumatol. 17, 994-1002 (1990).
    • (1990) J. Rheumatol. , vol.17 , pp. 994-1002
    • Wolfe, F.1    Hawley, D.J.2    Cathey, M.A.3
  • 66
    • 0036021133 scopus 로고    scopus 로고
    • Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study
    • Aletaha, D. & Smolen, J. S. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol. 29, 1631-1638 (2002).
    • (2002) J. Rheumatol. , vol.29 , pp. 1631-1638
    • Aletaha, D.1    Smolen, J.S.2
  • 67
    • 0036902026 scopus 로고    scopus 로고
    • The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses
    • Aletaha, D. & Smolen, J. S. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 41, 1367-1374 (2002).
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1367-1374
    • Aletaha, D.1    Smolen, J.S.2
  • 68
    • 0029869174 scopus 로고    scopus 로고
    • The effectiveness of early treatment with 'second-line' antirheumatic drugs: A randomized, controlled trial
    • van der Heide, A. et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. 124, 699-707 (1996).
    • (1996) Ann. Intern. Med. , vol.124 , pp. 699-707
    • van der Heide, A.1
  • 69
    • 0142107711 scopus 로고    scopus 로고
    • The benefit of very early refferal and therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis
    • Nell, V. et al. The benefit of very early refferal and therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Arthritis Rheum. 49, S334 (2002).
    • (2002) Arthritis Rheum. , vol.49
    • Nell, V.1
  • 70
    • 0030751946 scopus 로고    scopus 로고
    • Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalizine alone in early rheumatoid arthritis: A randomised trial
    • Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalizine alone in early rheumatoid arthritis: a randomised trial. Lancet 350, 309-318 (1997).
    • (1997) Lancet , vol.350 , pp. 309-318
    • Boers, M.1
  • 71
    • 0033535754 scopus 로고    scopus 로고
    • Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
    • FIN-RACo trial group
    • Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
    • (1999) Lancet , vol.353 , pp. 1568-1573
    • Mottonen, T.1
  • 72
    • 9244247260 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
    • O'Dell, J. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291 (1996).
    • (1996) N. Engl. J. Med. , vol.334 , pp. 1287-1291
    • O'Dell, J.1
  • 73
    • 0032957015 scopus 로고    scopus 로고
    • Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
    • Dougados, M. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58, 220-225 (1999).
    • (1999) Ann. Rheum. Dis. , vol.58 , pp. 220-225
    • Dougados, M.1
  • 74
    • 0027946325 scopus 로고
    • The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis
    • Felson, D. T., Anderson, J. J. & Meenan, R. F. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum. 37, 1487-1491 (1994).
    • (1994) Arthritis Rheum. , vol.37 , pp. 1487-1491
    • Felson, D.T.1    Anderson, J.J.2    Meenan, R.F.3
  • 75
    • 0030696346 scopus 로고    scopus 로고
    • Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
    • Haagsma, C. J., van Riel, P. L., de Jong, A. J. & van de Putte, L. B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial, Br. J. Rheumatol. 36, 1082-1088 (1997).
    • (1997) Br. J. Rheumatol. , vol.36 , pp. 1082-1088
    • Haagsma, C.J.1    van Riel, P.L.2    de Jong, A.J.3    van de Putte, L.B.4
  • 76
    • 0032693752 scopus 로고    scopus 로고
    • Combination DMARD therapy including corticosteroids in early rheumatoid arthritis
    • Mottonen, T. T., Hannonen, P. J. & Boers, M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. Clin. Exp. Rheumatol. 17, S59-S65 (1999).
    • (1999) Clin. Exp. Rheumatol. , vol.17
    • Mottonen, T.T.1    Hannonen, P.J.2    Boers, M.3
  • 77
    • 0036833533 scopus 로고    scopus 로고
    • Pharmacological management of early rheumatoid arthritis - Does combination therapy improve outcomes?
    • Dougados, M. & Smolen, J. S. Pharmacological management of early rheumatoid arthritis - does combination therapy improve outcomes? J. Rheumatol. 66, S20-S26 (2002).
    • (2002) J. Rheumatol. , vol.66
    • Dougados, M.1    Smolen, J.S.2
  • 78
    • 0029022389 scopus 로고
    • Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
    • The Methotrexate-Cyclosporine Combination Study Group
    • Tugwell, P. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333, 137-141 (1995).
    • (1995) N. Engl. J. Med. , vol.333 , pp. 137-141
    • Tugwell, P.1
  • 79
    • 0037027427 scopus 로고    scopus 로고
    • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    • Kremer, J. M. et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137, 726-733 (2002).
    • (2002) Ann. Intern. Med. , vol.137 , pp. 726-733
    • Kremer, J.M.1
  • 80
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    • Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
    • (1998) Arthritis Rheum. , vol.41 , pp. 1552-1563
    • Maini, R.N.1
  • 81
    • 0035056003 scopus 로고    scopus 로고
    • Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?
    • Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
    • (2001) Annu. Rev. Immunol. , vol.19 , pp. 163-196
    • Feldmann, M.1    Maini, R.N.2
  • 82
    • 0026039673 scopus 로고
    • Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
    • Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
    • (1991) EMBO J. , vol.10 , pp. 4025-4031
    • Keffer, J.1
  • 83
    • 0028143211 scopus 로고
    • Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
    • Elliott, M. J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (1994).
    • (1994) Lancet , vol.344 , pp. 1105-1110
    • Elliott, M.J.1
  • 84
    • 0034735842 scopus 로고    scopus 로고
    • Infliximab and methotrexate in the treatment of rheumatoid arthritis
    • Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
    • Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
    • (2000) N. Engl. J. Med. , vol.343 , pp. 1594-1602
    • Lipsky, P.E.1
  • 85
    • 0033611472 scopus 로고    scopus 로고
    • A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    • Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
    • (1999) N. Engl. J. Med. , vol.340 , pp. 253-259
    • Weinblatt, M.E.1
  • 86
    • 0013511183 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
    • Moreland, L. W. et al. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
    • (1997) N. Engl. J. Med. , vol.337 , pp. 141-147
    • Moreland, L.W.1
  • 87
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    • Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum, 48, 35-45 (2003).
    • (2003) Arthritis Rheum. , vol.48 , pp. 35-45
    • Weinblatt, M.E.1
  • 88
    • 0033768473 scopus 로고    scopus 로고
    • Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
    • Kempeni, J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann. Rheum. Dis. 59 S1, i44-i45 (2000).
    • (2000) Ann. Rheum. Dis. , vol.59 , Issue.S1
    • Kempeni, J.1
  • 89
    • 0036838681 scopus 로고    scopus 로고
    • Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
    • Furst, D. E. et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann. Rheum. Dis. 61 S2, ii2-ii7 (2002).
    • (2002) Ann. Rheum. Dis. , vol.61 , Issue.S2
    • Furst, D.E.1
  • 90
    • 0035846326 scopus 로고    scopus 로고
    • Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent
    • Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
    • (2001) N. Engl. J. Med. , vol.345 , pp. 1098-1104
    • Keane, J.1
  • 91
    • 0035674613 scopus 로고    scopus 로고
    • Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides
    • Mohan, N. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862-2869 (2001).
    • (2001) Arthritis Rheum. , vol.44 , pp. 2862-2869
    • Mohan, N.1
  • 93
    • 0034677123 scopus 로고    scopus 로고
    • Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
    • Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320(2000).
    • (2000) J. Exp. Med. , vol.191 , pp. 313-320
    • Horai, R.1
  • 94
    • 17444394445 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    • Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.41, 2196-2204 (1998).
    • (1998) Arthritis Rheum. , vol.41 , pp. 2196-2204
    • Bresnihan, B.1
  • 95
    • 0036190776 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    • Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 614-624
    • Cohen, S.1
  • 96
    • 0034083128 scopus 로고    scopus 로고
    • A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist inpatients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
    • Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist inpatients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
    • (2000) Arthritis Rheum. , vol.43 , pp. 1001-1009
    • Jiang, Y.1
  • 97
    • 1842602667 scopus 로고    scopus 로고
    • Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis
    • Konttinen, Y. T. et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. 68, 691-697 (1999).
    • (1999) Ann. Rheum. Dis. , vol.68 , pp. 691-697
    • Konttinen, Y.T.1
  • 99
    • 0035129903 scopus 로고    scopus 로고
    • ADAMTS: A novel family of extracellular matrix proteases
    • Tang, B. L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33, 33-44 (2001).
    • (2001) Int. J. Biochem. Cell Biol. , vol.33 , pp. 33-44
    • Tang, B.L.1
  • 101
    • 0035819527 scopus 로고    scopus 로고
    • Development of matrix metalloprotainase inhibitors in cancer therapy
    • Hidalgo, M. & Eckhardt, S. G. Development of matrix metalloprotainase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178-193 (2001).
    • (2001) J. Natl. Cancer Inst. , vol.93 , pp. 178-193
    • Hidalgo, M.1    Eckhardt, S.G.2
  • 102
    • 0034770450 scopus 로고    scopus 로고
    • Matrix metalloprotainase inhibitors in rheumatic diseases
    • Close, D. R. Matrix metalloprotainase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60 S3, iii62-iii67 (2001).
    • (2001) Ann. Rheum. Dis. , vol.60 , Issue.S3
    • Close, D.R.1
  • 103
    • 0036838574 scopus 로고    scopus 로고
    • Treatments no longer in development for rheumatoid arthritis
    • Keystone, E. Treatments no longer in development for rheumatoid arthritis. Ann. Rheum. Dis. 61 S2, ii43-ii45 (2002).
    • (2002) Ann. Rheum. Dis. , vol.61 , Issue.S2
    • Keystone, E.1
  • 104
    • 0034615550 scopus 로고    scopus 로고
    • Tissue inhibitors of metalloproteinases; evolution, structure and function
    • 1477
    • Brew, K., Dinakarpandian, D. & Nagase, H. Tissue inhibitors of metalloproteinases; evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283 (2000).
    • (2000) Biochim. Biophys. Acta , pp. 267-283
    • Brew, K.1    Dinakarpandian, D.2    Nagase, H.3
  • 105
    • 0035676661 scopus 로고    scopus 로고
    • Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice
    • Schett, G. et al. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. 44, 2888-2898 (2001).
    • (2001) Arthritis Rheum. , vol.44 , pp. 2888-2898
    • Schett, G.1
  • 106
    • 8044257704 scopus 로고    scopus 로고
    • A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
    • Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729-733 (1997).
    • (1997) Nature , vol.385 , pp. 729-733
    • Black, R.A.1
  • 107
    • 0034903680 scopus 로고    scopus 로고
    • Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis
    • Ohta, S. et al. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis. J. Rheumatol. 28, 1756-1763 (2001).
    • (2001) J. Rheumatol. , vol.28 , pp. 1756-1763
    • Ohta, S.1
  • 108
    • 0036082365 scopus 로고    scopus 로고
    • (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl -2'- (methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase
    • Beck, G. et al. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl -2'- (methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J. Pharmacol. Exp. Ther. 302, 390-396 (2002).
    • (2002) J. Pharmacol. Exp. Ther. , vol.302 , pp. 390-396
    • Beck, G.1
  • 109
    • 0034883069 scopus 로고    scopus 로고
    • Inhibition of tumor necrosis factor-alpha (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases
    • Conway, J. G, et al. Inhibition of tumor necrosis factor-alpha (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. 298, 900-908 (2001).
    • (2001) J. Pharmacol. Exp. Ther. , vol.298 , pp. 900-908
    • Conway, J.G.1
  • 110
    • 26544468999 scopus 로고    scopus 로고
    • Development of a novel dual TACE/MMP inhibitor for treatment of RA
    • Zhang, Y. et al. Development of a novel dual TACE/MMP inhibitor for treatment of RA, Arthritis Rheum. 46, S136 (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Zhang, Y.1
  • 111
    • 0034775522 scopus 로고    scopus 로고
    • Biology of TACE inhibition
    • Newton, R. C. et al. Biology of TACE inhibition. Ann. Rheum.Dis. 60 S3, iii25-iii32 (2001).
    • (2001) Ann. Rheum.Dis. , vol.60 , Issue.S3
    • Newton, R.C.1
  • 112
    • 17944381638 scopus 로고    scopus 로고
    • Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation
    • Ruuls, S. R. et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15, 533-543 (2001).
    • (2001) Immunity , vol.15 , pp. 533-543
    • Ruuls, S.R.1
  • 113
    • 0030698766 scopus 로고    scopus 로고
    • A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
    • Alexopoulou, L., Pasparakis, M. & Kollias, G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling, Eur. J. Immunol. 27, 2588-2592 (1997).
    • (1997) Eur. J. Immunol. , vol.27 , pp. 2588-2592
    • Alexopoulou, L.1    Pasparakis, M.2    Kollias, G.3
  • 114
    • 0029891449 scopus 로고    scopus 로고
    • Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α processing in RA synovial membrane cell cultures
    • Williams, L. M. et al. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α processing in RA synovial membrane cell cultures J. Clin. Invest. 97, 2833-2841 (1996).
    • (1996) J. Clin. Invest. , vol.97 , pp. 2833-2841
    • Williams, L.M.1
  • 115
    • 0026507126 scopus 로고
    • A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes
    • Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. Nature 356, 768-774 (1992).
    • (1992) Nature , vol.356 , pp. 768-774
    • Thornberry, N.A.1
  • 116
    • 0032194115 scopus 로고    scopus 로고
    • Generation of biologically active IL-1 β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1 β processing
    • Schonbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1 β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 β processing. J. Immunol. 161, 3340-3346 (1998).
    • (1998) J. Immunol. , vol.161 , pp. 3340-3346
    • Schonbeck, U.1    Mach, F.2    Libby, P.3
  • 117
    • 0032521457 scopus 로고    scopus 로고
    • Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1β converting enzyme (caspase-1)-deficient mice
    • Fantuzzi, G., Puren, A. J., Harding, M. W., Livingston, D. J. & Dinarello, C. A. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1β converting enzyme (caspase-1)-deficient mice. Blood 91, 2118-2125 (1998).
    • (1998) Blood , vol.91 , pp. 2118-2125
    • Fantuzzi, G.1    Puren, A.J.2    Harding, M.W.3    Livingston, D.J.4    Dinarello, C.A.5
  • 118
    • 0032031392 scopus 로고    scopus 로고
    • Post-translational processing of murine IL-1: Evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism
    • Perregaux, D. G. & Gabel, C. A. Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism. J. Immunol. 160, 2460-2477 (1998).
    • (1998) J. Immunol. , vol.160 , pp. 2460-2477
    • Perregaux, D.G.1    Gabel, C.A.2
  • 120
    • 0029971948 scopus 로고    scopus 로고
    • Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice
    • Ku, G., Faust, T., Lauffer, L. L., Livingston, D. J. & Harding, M. W. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8, 377-386 (1996).
    • (1996) Cytokine , vol.8 , pp. 377-386
    • Ku, G.1    Faust, T.2    Lauffer, L.L.3    Livingston, D.J.4    Harding, M.W.5
  • 121
    • 0242388248 scopus 로고    scopus 로고
    • Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient Phil trial in rheumatoid arthritis (RA)
    • Pavelka, K. et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient Phil trial in rheumatoid arthritis (RA). Abstr. Am. Coll. Rheumatol. 66th Ann. Sci. Meet. (2002).
    • (2002) Abstr. Am. Coll. Rheumatol. 66th Ann. Sci. Meet.
    • Pavelka, K.1
  • 122
    • 0036899591 scopus 로고    scopus 로고
    • Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP
    • Dell'Antonio, G., Quattrini, A., Cin, E. D., Fulgenzi, A. & Ferrero, M. E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 46, 3378-3385 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 3378-3385
    • Dell'Antonio, G.1    Quattrini, A.2    Cin, E.D.3    Fulgenzi, A.4    Ferrero, M.E.5
  • 123
    • 0037096207 scopus 로고    scopus 로고
    • Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response
    • Labasi, J. M. et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 168, 6436-6445 (2002).
    • (2002) J. Immunol. , vol.168 , pp. 6436-6445
    • Labasi, J.M.1
  • 124
    • 0034084163 scopus 로고    scopus 로고
    • Phosphorylation meets ubiquination: The control of NF-κB activity
    • Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
    • (2000) Annu. Rev. Immunol. , vol.18 , pp. 621-663
    • Karin, M.1    Ben-Neriah, Y.2
  • 125
    • 0000240724 scopus 로고    scopus 로고
    • Thompson, A. (ed.) (Academic Press, San Diego, CA)
    • Zhang, M. & Tracey, K. J. In The Cytokine Handbook. Thompson, A. (ed.) 517-548 (Academic Press, San Diego, CA, 1998).
    • (1998) The Cytokine Handbook , pp. 517-548
    • Zhang, M.1    Tracey, K.J.2
  • 126
    • 0033618337 scopus 로고    scopus 로고
    • Matrix metalloproteinases
    • Nagase, H. & Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494 (1999).
    • (1999) J. Biol. Chem. , vol.274 , pp. 21491-21494
    • Nagase, H.1    Woessner, J.F.2
  • 127
    • 0032428729 scopus 로고    scopus 로고
    • AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis
    • Han, Z. et al. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28, 197-208 (1998).
    • (1998) Autoimmunity , vol.28 , pp. 197-208
    • Han, Z.1
  • 128
    • 0033758633 scopus 로고    scopus 로고
    • Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase in synovial tissue and cells in rheumatoid arthritis
    • Schett, G. et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43, 2501-2512 (2000).
    • (2000) Arthritis Rheum. , vol.43 , pp. 2501-2512
    • Schett, G.1
  • 129
    • 0034887261 scopus 로고    scopus 로고
    • VX-745. Vertex Pharmaceuticals
    • Haddad, J. J. VX-745. Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs 2, 1070-1076 (2001).
    • (2001) Curr. Opin. Investig. Drugs , vol.2 , pp. 1070-1076
    • Haddad, J.J.1
  • 130
    • 0031803059 scopus 로고    scopus 로고
    • SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
    • Badger, A. M. et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161, 467-473 (1998).
    • (1998) J. Immunol. , vol.161 , pp. 467-473
    • Badger, A.M.1
  • 131
    • 0033578080 scopus 로고    scopus 로고
    • Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
    • Liverton, N. J. et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42, 2180-2190 (1999).
    • (1999) J. Med. Chem. , vol.42 , pp. 2180-2190
    • Liverton, N.J.1
  • 132
    • 0035086636 scopus 로고    scopus 로고
    • The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy
    • McIay, L. M. et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy Bioorg. Med. Chem. 9, 537-554 (2001).
    • (2001) Bioorg. Med. Chem. , vol.9 , pp. 537-554
    • McIay, L.M.1
  • 133
    • 0032745423 scopus 로고    scopus 로고
    • RWJ. 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
    • Wadsworth, S. A. et al. RWJ. 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291, 680-687 (1999).
    • (1999) J. Pharmacol. Exp. Ther. , vol.291 , pp. 680-687
    • Wadsworth, S.A.1
  • 134
    • 0036715931 scopus 로고    scopus 로고
    • Pyridinylimidazole based p38 MAP kinase inhibitors
    • Jackson, P. F. & Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2, 1011-1020 (2002).
    • (2002) Curr. Top. Med. Chem. , vol.2 , pp. 1011-1020
    • Jackson, P.F.1    Bullington, J.L.2
  • 135
    • 0035848384 scopus 로고    scopus 로고
    • RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency
    • Collis, A. J. et al. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg. Med. Chem. Lett. 11, 693-696 (2001).
    • (2001) Bioorg. Med. Chem. Lett. , vol.11 , pp. 693-696
    • Collis, A.J.1
  • 136
    • 0037019275 scopus 로고    scopus 로고
    • Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
    • Regan, J. et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008 (2002).
    • (2002) J. Med. Chem. , vol.45 , pp. 2994-3008
    • Regan, J.1
  • 137
    • 18344395134 scopus 로고    scopus 로고
    • Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
    • Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct. Biol. 9, 268-272 (2002).
    • (2002) Nature Struct. Biol. , vol.9 , pp. 268-272
    • Pargellis, C.1
  • 138
    • 0036719870 scopus 로고    scopus 로고
    • The non-diaryl heterocycle classes of p38 MAP kinase inhibitors
    • Cirillo, P. F., Pargellis, C. & Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med Chem. 2, 1021-1035 (2002).
    • (2002) Curr. Top. Med Chem. , vol.2 , pp. 1021-1035
    • Cirillo, P.F.1    Pargellis, C.2    Regan, J.3
  • 139
    • 0031934170 scopus 로고    scopus 로고
    • Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
    • Jackson, J. R. et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284, 687-692 (1998).
    • (1998) J. Pharmacol. Exp. Ther. , vol.284 , pp. 687-692
    • Jackson, J.R.1
  • 140
    • 0035000643 scopus 로고    scopus 로고
    • Suppression of the clinical and cytokine response to endotoxin by RWJ- 67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers
    • Fijen, J. W. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ- 67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124, 16-20 (2001).
    • (2001) Clin. Exp. Immunol. , vol.124 , pp. 16-20
    • Fijen, J.W.1
  • 141
    • 0033994234 scopus 로고    scopus 로고
    • Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation
    • Pirvola, U. et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J. Neurosci. 20, 43-50 (2000).
    • (2000) J. Neurosci. , vol.20 , pp. 43-50
    • Pirvola, U.1
  • 142
    • 0036844412 scopus 로고    scopus 로고
    • Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro
    • Bodmer, D., Gloddek, B., Ryan, A. F., Huverstuhl, J. & Brors, D. Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro. Laryngoscope 112, 2057-2061 (2002).
    • (2002) Laryngoscope , vol.112 , pp. 2057-2061
    • Bodmer, D.1    Gloddek, B.2    Ryan, A.F.3    Huverstuhl, J.4    Brors, D.5
  • 143
    • 0034931503 scopus 로고    scopus 로고
    • c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
    • Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73-81 (2001).
    • (2001) J. Clin. Invest. , vol.108 , pp. 73-81
    • Han, Z.1
  • 144
    • 0036445261 scopus 로고    scopus 로고
    • Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A downregulates c-myc gene expression and endothelial cell proliferation
    • Pintus, G. et al. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A downregulates c-myc gene expression and endothelial cell proliferation. Eur. J. Biochem. 269, 5861-5870 (2002).
    • (2002) Eur. J. Biochem. , vol.269 , pp. 5861-5870
    • Pintus, G.1
  • 145
    • 0036858359 scopus 로고    scopus 로고
    • Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury
    • Mori, T., Wang, X., Aoki, T. & Lo, E. H. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J. Neurotrauma 19, 1411-1419 (2002).
    • (2002) J. Neurotrauma , vol.19 , pp. 1411-1419
    • Mori, T.1    Wang, X.2    Aoki, T.3    Lo, E.H.4
  • 146
    • 0036839571 scopus 로고    scopus 로고
    • Is NF-κB a useful therapeutic target in rheumatoid arthritis?
    • Feldmann, M. et al. Is NF-κB a useful therapeutic target in rheumatoid arthritis? Ann. Rheum.Dis. 61 S2, ii13-ii18 (2002).
    • (2002) Ann. Rheum.Dis. , vol.61 , Issue.S2
    • Feldmann, M.1
  • 147
    • 0035139792 scopus 로고    scopus 로고
    • Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
    • Yamamoto, Y. & Gaynor, R. B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer J. Clin. Invest. 107, 135-142 (2001).
    • (2001) J. Clin. Invest. , vol.107 , pp. 135-142
    • Yamamoto, Y.1    Gaynor, R.B.2
  • 148
    • 0034489187 scopus 로고    scopus 로고
    • Naturally occurring and synthetic inhibitors of NF-κB functions
    • Umezawa, K., Ariga, A. & Matsumoto, N. Naturally occurring and synthetic inhibitors of NF-κB functions. Anticancer Drug Des. 15, 239-244 (2000).
    • (2000) Anticancer Drug Des. , vol.15 , pp. 239-244
    • Umezawa, K.1    Ariga, A.2    Matsumoto, N.3
  • 149
    • 15844381960 scopus 로고    scopus 로고
    • The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB
    • Pahl, H. L. et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB. J. Exp. Med. 183, 1829-1840 (1996).
    • (1996) J. Exp. Med. , vol.183 , pp. 1829-1840
    • Pahl, H.L.1
  • 150
    • 0033178749 scopus 로고    scopus 로고
    • Essential role of T cell NF-κB activation in collagen-induced arthritis
    • Seetharaman, R., Mora, A. L., Nabozny, G., Boothby, M. & Chen, J. Essential role of T cell NF-κB activation in collagen-induced arthritis. J. Immunol. 163, 1577-1583 (1999).
    • (1999) J. Immunol. , vol.163 , pp. 1577-1583
    • Seetharaman, R.1    Mora, A.L.2    Nabozny, G.3    Boothby, M.4    Chen, J.5
  • 151
    • 0036099012 scopus 로고    scopus 로고
    • Gliotoxin, an inhibitor of nuclear factor-κB, attenuates peptidoglycan-polysaccharide-induced colitis in rats
    • Fitzpatrick, L. R., Wang, J. & Le, T. Gliotoxin, an inhibitor of nuclear factor-κB, attenuates peptidoglycan-polysaccharide-induced colitis in rats. Inflamm. Bowel. Dis. 8, 159-167 (2002).
    • (2002) Inflamm. Bowel. Dis. , vol.8 , pp. 159-167
    • Fitzpatrick, L.R.1    Wang, J.2    Le, T.3
  • 152
    • 0037124207 scopus 로고    scopus 로고
    • Pyrazolo[3, 4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - A selectivity insight
    • Burchat, A. F. et al. Pyrazolo[3, 4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg. Mad. Chem. Lett. 12, 1687-1690 (2002).
    • (2002) Bioorg. Mad. Chem. Lett. , vol.12 , pp. 1687-1690
    • Burchat, A.F.1
  • 153
    • 0035124182 scopus 로고    scopus 로고
    • Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides
    • Sadeghi, R. et al. Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides. Int. Immunopharmacol. 1, 33-48 (2001).
    • (2001) Int. Immunopharmacol. , vol.1 , pp. 33-48
    • Sadeghi, R.1
  • 154
    • 0034654091 scopus 로고    scopus 로고
    • Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases
    • Yorgin, P. D. et al. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J. Immunol. 164, 2915-2923 (2000).
    • (2000) J. Immunol. , vol.164 , pp. 2915-2923
    • Yorgin, P.D.1
  • 155
    • 0033117811 scopus 로고    scopus 로고
    • Inhibition of p56(lck) tyrosine kinase by isothiazolones
    • Trevillyan, J. M. et al. Inhibition of p56(lck) tyrosine kinase by isothiazolones. Arch. Biochem. Biophys. 364, 19-29 (1999).
    • (1999) Arch. Biochem. Biophys. , vol.364 , pp. 19-29
    • Trevillyan, J.M.1
  • 156
    • 0034837053 scopus 로고    scopus 로고
    • Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection
    • Kamens, J. S., Ratnofsky, S. E. & Hirst, G. C. Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. Curr. Opin. Investig. Drugs 2, 1213-1219 (2001).
    • (2001) Curr. Opin. Investig. Drugs , vol.2 , pp. 1213-1219
    • Kamens, J.S.1    Ratnofsky, S.E.2    Hirst, G.C.3
  • 157
    • 0033607499 scopus 로고    scopus 로고
    • Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
    • Matsumoto, I. et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286, 1732-5 (1999).
    • (1999) Science , vol.286 , pp. 1732-1735
    • Matsumoto, I.1
  • 158
    • 0027139297 scopus 로고
    • Genes on the X chromosome affect development of collagen-induced arthritis in mice
    • Jansson, L. & Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin. Exp. Immunol. 94, 459-465 (1993).
    • (1993) Clin. Exp. Immunol. , vol.94 , pp. 459-465
    • Jansson, L.1    Holmdahl, R.2
  • 159
    • 0027399081 scopus 로고
    • Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
    • Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279-290 (1993).
    • (1993) Cell , vol.72 , pp. 279-290
    • Tsukada, S.1
  • 160
    • 0034657235 scopus 로고    scopus 로고
    • Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation
    • Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R. & Wortis, H. H. Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation. J. Exp. Med. 191, 1735-1744 (2000).
    • (2000) J. Exp. Med. , vol.191 , pp. 1735-1744
    • Bajpai, U.D.1    Zhang, K.2    Teutsch, M.3    Sen, R.4    Wortis, H.H.5
  • 161
    • 0037087438 scopus 로고    scopus 로고
    • Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance
    • Mukhopadhyay, S. et al. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J. Immunol. 168, 2914-2921 (2002).
    • (2002) J. Immunol. , vol.168 , pp. 2914-2921
    • Mukhopadhyay, S.1
  • 162
    • 0033515450 scopus 로고    scopus 로고
    • Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl )propenamide]
    • Mahajan, S. et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl propenamide]. J. Biol. Chem. 274, 9587-9599 (1999).
    • (1999) J. Biol. Chem. , vol.274 , pp. 9587-9599
    • Mahajan, S.1
  • 164
    • 0038544296 scopus 로고    scopus 로고
    • Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumour necrosis factor α production
    • (in the press)
    • Horwood, N. J. et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumour necrosis factor α production J. Exp. Med. (in the press).
    • J. Exp. Med.
    • Horwood, N.J.1
  • 165
    • 0035750533 scopus 로고    scopus 로고
    • B cell signaling. Introduction
    • Tsubata, T. & Wienands, J. B cell signaling. Introduction, Int. Rev. Immunol. 20, 675-678 (2001).
    • (2001) Int. Rev. Immunol. , vol.20 , pp. 675-678
    • Tsubata, T.1    Wienands, J.2
  • 166
    • 0036796777 scopus 로고    scopus 로고
    • Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial
    • Choy, E. H. et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41, 1133-1137 (2002).
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1133-1137
    • Choy, E.H.1
  • 167
    • 0037315157 scopus 로고    scopus 로고
    • Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study
    • Rutgeerts, P. et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study Aliment. Pharmacol. Ther. 17, 185-192 (2003).
    • (2003) Aliment. Pharmacol. Ther. , vol.17 , pp. 185-192
    • Rutgeerts, P.1
  • 168
    • 0036822909 scopus 로고    scopus 로고
    • Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis
    • Coxon, A. et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 46, 2604-2612 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 2604-2612
    • Coxon, A.1
  • 169
    • 0036735138 scopus 로고    scopus 로고
    • Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage
    • Abramson, S. B. & Amin, A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41, 972-980 (2002).
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 972-980
    • Abramson, S.B.1    Amin, A.2
  • 170
    • 0033179534 scopus 로고    scopus 로고
    • Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
    • Charles, P. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521-1528 (1999).
    • (1999) J. Immunol. , vol.163 , pp. 1521-1528
    • Charles, P.1
  • 171
    • 0032536542 scopus 로고    scopus 로고
    • Interleukin 6 is required for the development of collagen-induced arthritis
    • Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
    • (1998) J. Exp. Med. , vol.187 , pp. 461-468
    • Alonzi, T.1
  • 172
    • 0027402917 scopus 로고
    • Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
    • Wending, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody J. Rheumatol.20, 259-262 (1993).
    • (1993) J. Rheumatol. , vol.20 , pp. 259-262
    • Wending, D.1    Racadot, E.2    Wijdenes, J.3
  • 173
    • 0036899812 scopus 로고    scopus 로고
    • Therapeutic benefit of blocking interleukin-6 activity with an anti- interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial
    • Choy, E. H. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti- interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46, 3143-3150 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 3143-3150
    • Choy, E.H.1
  • 174
    • 84925549112 scopus 로고    scopus 로고
    • The paradigm of IL-6: From basic science to medicine
    • Naka, T., Nishimoto, N. & Kishimoto, T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4 S3, S233-S242 (2002).
    • (2002) Arthritis Res. , vol.4 , Issue.S3
    • Naka, T.1    Nishimoto, N.2    Kishimoto, T.3
  • 175
    • 0027461913 scopus 로고
    • Interleukin-2 receptor-directed therapies: Antibody-or cytokine-based targeting molecules
    • Strop, T. B., Kelley, V. R., Murphy, J. R., Nichols, J. & Woodworth, T. G. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu. Rev. Med. 44, 343-353 (1993).
    • (1993) Annu. Rev. Med. , vol.44 , pp. 343-353
    • Strop, T.B.1    Kelley, V.R.2    Murphy, J.R.3    Nichols, J.4    Woodworth, T.G.5
  • 176
    • 0023718514 scopus 로고
    • Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody
    • Banerjee, S., Wei, B. Y., Hillman, K., Luthra, H. S. & David, C. S. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody J. Immunol. 141, 1150-1154 (1988).
    • (1988) J. Immunol. , vol.141 , pp. 1150-1154
    • Banerjee, S.1    Wei, B.Y.2    Hillman, K.3    Luthra, H.S.4    David, C.S.5
  • 177
    • 0036889625 scopus 로고    scopus 로고
    • Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
    • Shao, R. H., Tian, X., Gorgun, G., Urbano, A. G., & Foss, F. M. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leuk. Res. 26, 1077-1083 (2002).
    • (2002) Leuk. Res. , vol.26 , pp. 1077-1083
    • Shao, R.H.1    Tian, X.2    Gorgun, G.3    Urbano, A.G.4    Foss, F.M.5
  • 178
    • 0028990380 scopus 로고
    • Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
    • Gottlieb, S. L. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442-447 (1995).
    • (1995) Nature Med. , vol.1 , pp. 442-447
    • Gottlieb, S.L.1
  • 179
    • 0029164940 scopus 로고
    • Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension
    • Moreland, L. W. et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum. 38, 1177-1186 (1995).
    • (1995) Arthritis Rheum. , vol.38 , pp. 1177-1186
    • Moreland, L.W.1
  • 180
    • 0035166183 scopus 로고    scopus 로고
    • Role of anti-interleukin-2 receptor antibodies in kidney transplantation
    • Cibrilk, D. M., Kaplan, B. & Meier-Kriesche, H. U. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs. 15, 655-666 (2001).
    • (2001) BioDrugs , vol.15 , pp. 655-666
    • Cibrilk, D.M.1    Kaplan, B.2    Meier-Kriesche, H.U.3
  • 181
    • 0031042456 scopus 로고    scopus 로고
    • Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
    • McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
    • (1997) Nature Med. , vol.3 , pp. 189-195
    • McInnes, I.B.1    Leung, B.P.2    Sturrock, R.D.3    Field, M.4    Liew, F.Y.5
  • 182
    • 0032103993 scopus 로고    scopus 로고
    • Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology
    • Ruchatz, H., Leung, B. P., Wei, X. Q., McInnes, I. B. & Liew, F. Y. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160, 5654-5660 (1998).
    • (1998) J. Immunol. , vol.160 , pp. 5654-5660
    • Ruchatz, H.1    Leung, B.P.2    Wei, X.Q.3    McInnes, I.B.4    Liew, F.Y.5
  • 183
    • 0033041866 scopus 로고    scopus 로고
    • Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis
    • Butler, D. M., Malfait A. M., Maini, R. N., Brennan, F. M. & Feldmann, M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29, 2205-2212 (1999).
    • (1999) Eur. J. Immunol. , vol.29 , pp. 2205-2212
    • Butler, D.M.1    Malfait, A.M.2    Maini, R.N.3    Brennan, F.M.4    Feldmann, M.5
  • 184
    • 0032743708 scopus 로고    scopus 로고
    • A proinflammatory role for IL-18 in rheumatoid arthritis
    • Gracie, J. A. et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest 104, 1393-1401 (1999).
    • (1999) J. Clin. Invest. , vol.104 , pp. 1393-1401
    • Gracie, J.A.1
  • 185
    • 0024490105 scopus 로고
    • Endotoxin-induced serum factor that stimulates γ-interferon production
    • Nakamura, K., Okamura, H., Wada, M., Nagata, K. & Tamura, T. Endotoxin-induced serum factor that stimulates γ-interferon production. Infect. Immun. 57, 590-595 (1989).
    • (1989) Infect. Immun. , vol.57 , pp. 590-595
    • Nakamura, K.1    Okamura, H.2    Wada, M.3    Nagata, K.4    Tamura, T.5
  • 186
    • 0035173776 scopus 로고    scopus 로고
    • Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18
    • Wei, X. Q., Leung, B. P., Arthur, H. M., McInnes, I. B. & Liew, F. Y. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 166, 517-521 (2001).
    • (2001) J. Immunol. , vol.166 , pp. 517-521
    • Wei, X.Q.1    Leung, B.P.2    Arthur, H.M.3    McInnes, I.B.4    Liew, F.Y.5
  • 187
    • 0035664487 scopus 로고    scopus 로고
    • Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis
    • Plater-Zyberk, C. et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108, 1825-1832 (2001).
    • (2001) J. Clin. Invest. , vol.108 , pp. 1825-1832
    • Plater-Zyberk, C.1
  • 188
    • 0032939156 scopus 로고    scopus 로고
    • Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
    • Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963-970 (1999).
    • (1999) Arthritis Rheum. , vol.42 , pp. 963-970
    • Chabaud, M.1
  • 189
    • 0033136695 scopus 로고    scopus 로고
    • NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-,and IL-1β-induced chemokine promoter activation in intestinal epithelial cells
    • Awane, M., Andres, P. G., Li, D. J. & Reinecker, H. C. NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-,and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J. Immunol. 162, 5337-5344 (1999).
    • (1999) J. Immunol. , vol.162 , pp. 5337-5344
    • Awane, M.1    Andres, P.G.2    Li, D.J.3    Reinecker, H.C.4
  • 190
    • 0035078953 scopus 로고    scopus 로고
    • Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages
    • Jovanovic, D. V. et al. Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages. J. Rheumatol. 28, 712-718 (2001).
    • (2001) J. Rheumatol. , vol.28 , pp. 712-718
    • Jovanovic, D.V.1
  • 191
    • 0034966563 scopus 로고    scopus 로고
    • The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model
    • Chibaud M. & Miossec, P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44, 1293-1303 (2001).
    • (2001) Arthritis Rheum. , vol.44 , pp. 1293-1303
    • Chibaud, M.1    Miossec, P.2
  • 192
    • 0242293743 scopus 로고    scopus 로고
    • Smolen, J. S. & Lipsky, P. E. (eds.) (Martin Dunitz, London-New York)
    • Szekanecz, Z., Kim, J. & Koch, A. E. In Targeted Therapies in Rheumatology. Smolen, J. S. & Lipsky, P. E. (eds.) 345-357 (Martin Dunitz, London-New York, 2003).
    • (2003) Targeted Therapies in Rheumatology , pp. 345-357
    • Szekanecz, Z.1    Kim, J.2    Koch, A.E.3
  • 193
    • 0034568503 scopus 로고    scopus 로고
    • CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis
    • Zapico,-I. et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 1, 288-289 (2000).
    • (2000) Genes Immun. , vol.1 , pp. 288-289
    • Zapico, I.1
  • 194
    • 0036803279 scopus 로고    scopus 로고
    • Chemokines, chemokine receptors and small-molecule antagonists: Recent developments
    • Onuffer, J. J. & Horuk, R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments, Trends Pharmacol. Sci. 23, 459-467 (2002).
    • (2002) Trends Pharmacol. Sci. , vol.23 , pp. 459-467
    • Onuffer, J.J.1    Horuk, R.2
  • 195
    • 0035865316 scopus 로고    scopus 로고
    • Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: A new strategy in the treatment of chronic inflammatory diseases and HIV
    • Bruhl, H., Cihak, J., Stangassinger, M., Schlondorff, D. & Mack, M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV J. Immunol. 166, 2420-2426 (2001).
    • (2001) J. Immunol. , vol.166 , pp. 2420-2426
    • Bruhl, H.1    Cihak, J.2    Stangassinger, M.3    Schlondorff, D.4    Mack, M.5
  • 196
    • 0034814370 scopus 로고    scopus 로고
    • Neutralization of vascular endothelial growth factor prevents collagen- induced arthritis and ameliorates established disease in mice
    • Sone, H. et al. Neutralization of vascular endothelial growth factor prevents collagen- induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. 281, 562-568 (2001).
    • (2001) Biochem. Biophys. Res. Commun. , vol.281 , pp. 562-568
    • Sone, H.1
  • 198
    • 0037143764 scopus 로고    scopus 로고
    • VEGF-Trap: A VEGF blocker with potent anti-tumor effects
    • Holash, J. et al. VEGF-Trap: a VEGF blocker with potent anti-tumor effects. Proc. Natl Acad. Sci. USA 99, 11393-11398 (2002).
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , pp. 11393-11398
    • Holash, J.1
  • 199
    • 0036913264 scopus 로고    scopus 로고
    • Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4
    • Tarner, I. H. et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol. 105, 304-314 (2002).
    • (2002) Clin. Immunol. , vol.105 , pp. 304-314
    • Tarner, I.H.1
  • 200
    • 0002130296 scopus 로고    scopus 로고
    • rHu IL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study
    • van den Bosch, F. et al. rHu IL-4 in subjects with active rheumatoid arthritis (RA): a phase I dose escalating safety study. Arthritis Rheum. 41, S56 (1998).
    • (1998) Arthritis Rheum. , vol.41
    • van den Bosch, F.1
  • 201
    • 0002492007 scopus 로고    scopus 로고
    • rHuIL-10 (Tenovil) plus methotrexate (MTX) in active rheumatoid arthritis: A phase I/II study
    • Weinblatt, M. E. et al. rHuIL-10 (Tenovil) plus methotrexate (MTX) in active rheumatoid arthritis: A phase I/II study. Arthritis Rheum. 42 S170 (1999).
    • (1999) Arthritis Rheum. , vol.42
    • Weinblatt, M.E.1
  • 202
    • 0000428990 scopus 로고    scopus 로고
    • rHu IL-10 in jubjects with active rheumatoid arthritis: A phase I cytokine response study
    • Maini, R. N. et al. rHu IL-10 in jubjects with active rheumatoid arthritis: A phase I cytokine response study. Arthritis Rheum. 41, S224 (1998).
    • (1998) Arthritis Rheum. , vol.41
    • Maini, R.N.1
  • 203
    • 0036667140 scopus 로고    scopus 로고
    • Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines
    • van Roon, J. A., Bijlsma, J. W. & Lafeber, F. P. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr. Opin. Investig. Drugs 3, 1011-1016 (2002).
    • (2002) Curr. Opin. Investig. Drugs , vol.3 , pp. 1011-1016
    • van Roon, J.A.1    Bijlsma, J.W.2    Lafeber, F.P.3
  • 204
    • 0034280613 scopus 로고    scopus 로고
    • Clinical efficacy of rhIL-11
    • Reynolds, C. H. Clinical efficacy of rhIL-11. Oncology (Huntingt) 14, 32-40 (2000).
    • (2000) Oncology (Huntingt) , vol.14 , pp. 32-40
    • Reynolds, C.H.1
  • 205
    • 17844403234 scopus 로고    scopus 로고
    • Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
    • Moreland, L. et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 3, 247-252,(2001).
    • (2001) Arthritis Res. , vol.3 , pp. 247-252
    • Moreland, L.1
  • 206
    • 0029797868 scopus 로고    scopus 로고
    • Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
    • Bessis, N. et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13 Eur. J. Immunol. 26, 2399-2403 (1996).
    • (1996) Eur. J. Immunol. , vol.26 , pp. 2399-2403
    • Bessis, N.1
  • 207
    • 0034284226 scopus 로고    scopus 로고
    • Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium
    • Woods, J. M. et al. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J. Immunol. 165, 2755-2763 (2000).
    • (2000) J. Immunol. , vol.165 , pp. 2755-2763
    • Woods, J.M.1
  • 208
    • 0026767264 scopus 로고
    • Recombinant human interferon-γ in the treatment of rheumatoid arthritis: Double blind placebo controlled study
    • Machold, K. P., Neumann, K. & Smolen, J. S. Recombinant human interferon-γ in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann. Rheum.Dis. 51, 1039-1043(1992).
    • (1992) Ann. Rheum.Dis. , vol.51 , pp. 1039-1043
    • Machold, K.P.1    Neumann, K.2    Smolen, J.S.3
  • 209
    • 0025239792 scopus 로고
    • Prospective two-year followup of recombinant interferon-γ in rheumatoid arthritis
    • Cannon, G. W. et al. Prospective two-year followup of recombinant interferon-γ in rheumatoid arthritis. J. Rheumatol. 17, 304-310 (1990).
    • (1990) J. Rheumatol. , vol.17 , pp. 304-310
    • Cannon, G.W.1
  • 210
    • 0027731536 scopus 로고
    • Prospective 5-year followup of recombinant interferon-γ in rheumatoid arthritis
    • Cannon, G. W. et al. Prospective 5-year followup of recombinant interferon-γ in rheumatoid arthritis. J. Rheumatol. 20, 1867-1873 (1993).
    • (1993) J. Rheumatol. , vol.20 , pp. 1867-1873
    • Cannon, G.W.1
  • 211
    • 0026316320 scopus 로고
    • Induction of systemic lupus erythematosus by interferon-γ in a patient with rheumatoid arthritis
    • Graninger, W. B. et al. Induction of systemic lupus erythematosus by interferon-γ in a patient with rheumatoid arthritis. J. Rheumatol. 18, 1621-1622 (1991).
    • (1991) J. Rheumatol. , vol.18 , pp. 1621-1622
    • Graninger, W.B.1
  • 212
    • 0036796835 scopus 로고    scopus 로고
    • Repeat-cycle study of high-dose intravenous 4162W94 ani-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo- controlled trial
    • Choy, E. H. et al. Repeat-cycle study of high-dose intravenous 4162W94 ani-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo- controlled trial. Rheumatology (Oxford) 41, 1142-1148 (2002).
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1142-1148
    • Choy, E.H.1
  • 213
    • 8944229691 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
    • The Xoma RA Investigator Group
    • Olsen, N. J. et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 39, 1102-1108 (1996).
    • (1996) Arthritis Rheum. , vol.39 , pp. 1102-1108
    • Olsen, N.J.1
  • 214
    • 0033062691 scopus 로고    scopus 로고
    • CD28/CTLA-4 and CD80/CD86 families: Signaling and function
    • Slavik, J. M., Hutchcroft, J. E. & Bierer, B. E. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol. Res. 19, 1-24 (1999).
    • (1999) Immunol. Res. , vol.19 , pp. 1-24
    • Slavik, J.M.1    Hutchcroft, J.E.2    Bierer, B.E.3
  • 215
    • 0038386405 scopus 로고    scopus 로고
    • A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA294 administered intravenously to subjects with rheumatoid arthritis
    • Moreland, L. W. et al. A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA294 administered intravenously to subjects with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
    • (2001) Arthritis Rheum. , vol.44
    • Moreland, L.W.1
  • 216
    • 0013304005 scopus 로고    scopus 로고
    • A phase 2B multi-center randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate
    • Kremer, J. et al. A phase 2B multi-center randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate. Arthritis Rheum. 46, S203 (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Kremer, J.1
  • 217
    • 0013218378 scopus 로고    scopus 로고
    • A pilot, multi-center, randomized, double blind, placebo controlled study of a co-stimulation blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis
    • Weinblatt, M. E. et al. A pilot, multi-center, randomized, double blind, placebo controlled study of a co-stimulation blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum. 46 S204 (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Weinblatt, M.E.1
  • 218
    • 0034811018 scopus 로고    scopus 로고
    • Treatment of autoimmunity by inhibition of T cell co-stimulation
    • Dalkh, D. I. & Wofsy D. Treatment of autoimmunity by inhibition of T cell co-stimulation. Adv. Exp. Med. Biol. 490, 113-117 (2001).
    • (2001) Adv. Exp. Med. Biol. , vol.490 , pp. 113-117
    • Dalkh, D.I.1    Wofsy, D.2
  • 219
    • 0035129767 scopus 로고    scopus 로고
    • The CD40/CD154 receptor/ligand dyad
    • Schonbeck, U. & Libby, P. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58, 4-43 (2001).
    • (2001) Cell Mol. Life Sci. , vol.58 , pp. 4-43
    • Schonbeck, U.1    Libby, P.2
  • 220
    • 0036170440 scopus 로고    scopus 로고
    • Activation and inhibition of lymphocytes by co-stimulation
    • Frauwirth, K. A. & Thompson, C. B. Activation and inhibition of lymphocytes by co-stimulation. J. Clin. Invest. 109, 295-299 (2002).
    • (2002) J. Clin. Invest. , vol.109 , pp. 295-299
    • Frauwirth, K.A.1    Thompson, C.B.2
  • 221
    • 0036676817 scopus 로고    scopus 로고
    • Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells
    • De Vita, S. et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells, Arthritis Rheum. 46, 2029-2033 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 2029-2033
    • De Vita, S.1
  • 222
    • 0038386557 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo-controlled trial in patients with rheumatoid arthritis
    • Edwards, J. C. W. et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 46, S197 (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Edwards, J.C.W.1
  • 223
    • 0033746843 scopus 로고    scopus 로고
    • Immunoadsorption for the treatment of rheumatoid arthritis: Final results of a randomized trial
    • Proscribe Trial Investigators
    • Furst, D., Felson, D., Thoren, G. & Gendreau, R. M. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Proscribe Trial Investigators. Ther. Apher. 4, 363-373 (2000).
    • (2000) Ther. Apher. , vol.4 , pp. 363-373
    • Furst, D.1    Felson, D.2    Thoren, G.3    Gendreau, R.M.4
  • 225
    • 0037234358 scopus 로고    scopus 로고
    • Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis
    • Nabbe, K. C. et al, Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum. 48, 255-265 (2003).
    • (2003) Arthritis Rheum. , vol.48 , pp. 255-265
    • Nabbe, K.C.1
  • 227
    • 0242293744 scopus 로고    scopus 로고
    • Smolen, J. S. & Lipsky, P. E. (eds.), (Martin Dunitz, London-New York)
    • Holers, V. M. In Targeted Therapies in Rheumatology. Smolen, J. S. & Lipsky, P. E. (eds.), pp. 167-180 (Martin Dunitz, London-New York, 2003).
    • (2003) Targeted Therapies in Rheumatology , pp. 167-180
    • Holers, V.M.1
  • 228
    • 0034190238 scopus 로고    scopus 로고
    • Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades
    • Hubbard, A. K. & Rothlein, R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radio. Biol. Med. 28, 1379-1386 (2000).
    • (2000) Free Radio. Biol. Med. , vol.28 , pp. 1379-1386
    • Hubbard, A.K.1    Rothlein, R.2
  • 229
    • 0028355977 scopus 로고
    • Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1
    • Kavanaugh, A. F. et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37, 992-999 (1994).
    • (1994) Arthritis Rheum. , vol.37 , pp. 992-999
    • Kavanaugh, A.F.1
  • 230
    • 0029739255 scopus 로고    scopus 로고
    • A phase I/II open label study of the safety and efficacy of an anti- ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis
    • Kavanaugh, A. F. et al. A phase I/II open label study of the safety and efficacy of an anti- ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. 23, 1338-1344 (1996).
    • (1996) J. Rheumatol. , vol.23 , pp. 1338-1344
    • Kavanaugh, A.F.1
  • 231
    • 0030911156 scopus 로고    scopus 로고
    • Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody
    • Kavanaugh, A. F., Schulze-Koops, H., Davis, L. S. & Lipsky, P. E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 40, 849-853 (1997).
    • (1997) Arthritis Rheum. , vol.40 , pp. 849-853
    • Kavanaugh, A.F.1    Schulze-Koops, H.2    Davis, L.S.3    Lipsky, P.E.4
  • 233
    • 0034695921 scopus 로고    scopus 로고
    • Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength
    • Chellaiah, M. et al. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell Biol. 148, 665-678 (2000).
    • (2000) J. Cell Biol. , vol.148 , pp. 665-678
    • Chellaiah, M.1
  • 234
    • 0035150588 scopus 로고    scopus 로고
    • Disease-modifying activity of SB 273005, an orally active, nonpeptide αVβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
    • Badger, A. M. et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide αVβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 44, 128-137 (2001).
    • (2001) Arthritis Rheum. , vol.44 , pp. 128-137
    • Badger, A.M.1
  • 235
    • 0036839554 scopus 로고    scopus 로고
    • Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
    • Wilder, R. L. Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 S2, ii96-ii99 (2002).
    • (2002) Ann. Rheum. Dis. , vol.61 , Issue.S2
    • Wilder, R.L.1
  • 236
    • 0035746070 scopus 로고    scopus 로고
    • Anti-adhesion antibodies efalizumab, a humanized anti-CD11 a monoclonal antibody
    • Dedrick, R. L., Walicke, P. & Garovoy, M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11 a monoclonal antibody. Transol. Immunol. 9, 181-186 (2002).
    • (2002) Transol. Immunol. , vol.9 , pp. 181-186
    • Dedrick, R.L.1    Walicke, P.2    Garovoy, M.3
  • 237
    • 0037413468 scopus 로고    scopus 로고
    • Natalizumab for active Crohn's disease
    • Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , pp. 24-32
    • Ghosh, S.1
  • 238
    • 0037413467 scopus 로고    scopus 로고
    • A controlled trial of natalizumab for relapsing multiple sclerosis
    • Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , pp. 15-23
    • Miller, D.H.1
  • 239
    • 0036822279 scopus 로고    scopus 로고
    • Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
    • Kraan, M. C. et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 46, 2776-2784 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 2776-2784
    • Kraan, M.C.1
  • 240
    • 0036895587 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
    • Krueger, G. G. et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821-833 (2002).
    • (2002) J. Am. Acad. Dermatol. , vol.47 , pp. 821-833
    • Krueger, G.G.1
  • 241
    • 0036377106 scopus 로고    scopus 로고
    • Biological aspects of signal transduction by cell adhesion receptors
    • Alahari, S. K., Reddig, P. J. & Juliano, R. L. Biological aspects of signal transduction by cell adhesion receptors. Int. Rev. Cytol. 220, 145-184 (2002).
    • (2002) Int. Rev. Cytol. , vol.220 , pp. 145-184
    • Alahari, S.K.1    Reddig, P.J.2    Juliano, R.L.3
  • 242
    • 0034948339 scopus 로고    scopus 로고
    • Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
    • Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).
    • (2001) Nature Med. , vol.7 , pp. 687-692
    • Weitz-Schmidt, G.1
  • 243
    • 0036780681 scopus 로고    scopus 로고
    • Toll-like receptors as potential therapeutic targets for multiple diseases
    • Zuany-Amorim, C., Hastewell, J. & Walker, C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nature Rev. Drug Discov. 1, 797-807 (2002).
    • (2002) Nature Rev. Drug Discov. , vol.1 , pp. 797-807
    • Zuany-Amorim, C.1    Hastewell, J.2    Walker, C.3
  • 244
    • 0037378466 scopus 로고    scopus 로고
    • Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium
    • Seibl, R. et al. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162, 1221-1227 (2003).
    • (2003) Am. J. Pathol. , vol.162 , pp. 1221-1227
    • Seibl, R.1
  • 245
    • 0031894140 scopus 로고    scopus 로고
    • Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
    • Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998).
    • (1998) Am. J. Pathol. , vol.152 , pp. 943-951
    • Gravallese, E.M.1
  • 246
    • 0036898425 scopus 로고    scopus 로고
    • Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis
    • Bolon, B. et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum. 46, 3121-3135 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 3121-3135
    • Bolon, B.1
  • 247
    • 0036185343 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
    • Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785-792 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 785-792
    • Redlich, K.1
  • 248
    • 0033581952 scopus 로고    scopus 로고
    • Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    • Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
    • (1999) Nature , vol.402 , pp. 304-309
    • Kong, Y.Y.1
  • 249
    • 0035153246 scopus 로고    scopus 로고
    • TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
    • Pettit, A. R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
    • (2001) Am. J. Pathol. , vol.159 , pp. 1689-1699
    • Pettit, A.R.1
  • 250
    • 0035139584 scopus 로고    scopus 로고
    • The effect of a single dose of osteoprotegerin in postmenopausal women
    • Bekker, P. J. et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
    • (2001) J. Bone Miner. Res. , vol.16 , pp. 348-360
    • Bekker, P.J.1
  • 251
    • 0036250129 scopus 로고    scopus 로고
    • Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines
    • Heikkila, P. et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13, 245-254 (2002).
    • (2002) Anticancer Drugs , vol.13 , pp. 245-254
    • Heikkila, P.1
  • 252
    • 0030007961 scopus 로고    scopus 로고
    • Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial
    • Eggelmeijer, F. et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39, 396-402 (1996).
    • (1996) Arthritis Rheum. , vol.39 , pp. 396-402
    • Eggelmeijer, F.1
  • 253
    • 0026561081 scopus 로고
    • The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials
    • Smolen, J. S. The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials. Br. J. Rheumatol. 31, 219-220 (1992).
    • (1992) Br. J. Rheumatol. , vol.31 , pp. 219-220
    • Smolen, J.S.1
  • 254
    • 0027238592 scopus 로고
    • The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
    • Felson, D. T. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 36, 729-740 (1993).
    • (1993) Arthritis Rheum. , vol.36 , pp. 729-740
    • Felson, D.T.1
  • 255
    • 0033019626 scopus 로고    scopus 로고
    • ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis
    • van Gestel, A. M. et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis. J. Rheumatol. 26, 705-711 (1999).
    • (1999) J. Rheumatol. , vol.26 , pp. 705-711
    • van Gestel, A.M.1
  • 256
    • 0034123087 scopus 로고    scopus 로고
    • Treatment with LEF slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of LEF in patients with active rheumatoid arthritis
    • Sharp, J. T., Strand, V., Leung, H., Hurley, F. & Loew-Friedrich, I. Treatment with LEF slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of LEF in patients with active rheumatoid arthritis. Arthritis Rheum. 43, 495-505 (2000).
    • (2000) Arthritis Rheum. , vol.43 , pp. 495-505
    • Sharp, J.T.1    Strand, V.2    Leung, H.3    Hurley, F.4    Loew-Friedrich, I.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.